Abstract: Compositions and methods are provided for intranasal delivery of interferon-? yielding improved pharmacokinetic and pharmacodynamic results. In certain aspects of the invention, the interferon-? is delivered to the intranasal mucosa along with one or more intranasal delivery-enhancing agent(s) to yield substantially increased absorption and/or bioavailability of the interferon-? and/or a substantially decreased time to maximal concentration of interferon-? in a tissue of a subject as compared to controls where the interferon-? is administered to the same intranasal site alone or formulated according to previously disclosed reports. The enhancement of intranasal delivery of interferon-? according to the methods and compositions of the present invention allows for the effective pharmaceutical use of these agents to treat a variety of diseases and conditions in mammalian subjects.

Abstract: Pharmaceutical formulations are described comprising at least one growth hormone and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the growth hormone. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of growth hormone to the blood plasma, for example, by yielding a peak concentration (Cmax) of the growth hormone in an hepatic portal vein or a blood plasma of the subject that is 20% or greater compared to a peak concentration of the growth hormone in the hepatic portal vein or the blood plasma of the subject following administration to the subject of a same concentration or dose of the growth hormone to the subject by subcutaneous injection. Exemplary formulations and methods within the invention utilize human growth hormone as the hormone.

Abstract: Compositions and methods are provided for intranasal delivery of interferon-&bgr; yielding improved pharmacokinetic and pharmacodynamic results. In certain aspects of the invention, the interferon-&bgr; is delivered to the intranasal mucosa along with one or more intranasal delivery-enhancing agent(s) to yield substantially increased absorption and/or bioavailability of the interferon-&bgr; and/or a substantially decreased time to maximal concentration of interferon-&bgr; in a tissue of a subject as compared to controls where the interferon-&bgr; is administered to the same intranasal site alone or formulated according to previously disclosed reports. The enhancement of intranasal delivery of interferon-&bgr; according to the methods and compositions of the present invention allows for the effective pharmaceutical use of these agents to treat a variety of diseases and conditions in mammalian subjects.